secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bluejay Diagnostics, Inc. (BJDX)
CIK:        0001704287
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001213900-26-053295
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bluejay Diagnostics Q1 2026: net loss $1.9M, SYMON-II study at 680 of 750 patients
--------------------------------------------------------------------------------

- Cash and equivalents $3.7M as of Mar 31, 2026; net loss $1.9M unchanged YoY.
- SYMON-II pivotal study enrollment at ~680 patients toward target of 750.
- Resolved manufacturing issues with Sanyoseiko; progressing toward analytical/clinical validation.
- Continuing FDA 510(k) strategy for Symphony IL-6 test after validation activities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1704287/000121390026053295/0001213900-26-053295-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1704287/000121390026053295/ea0289580-8k_bluejay.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-053295

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer